Aptah is a biotech startup focused on novel RNA therapies initially targeting cancer and neurodegenerative diseases.

Read more


Using our ASMO platform, we designed a molecule able to modulate pathogenic snRNPs, which arrest proteins that regulate autophagy, organelles transport, cell proliferation, growth and migration.

Read more

Neurodegenerative diseases - Alzheimer's

Our first drug for neurodegenerative diseases is targeting snRNPs related to AD. Aggregation, over activation and mislocalization of snRNPs could contribute to neurodegeneration by altering patterns of protein synthesis, post translational modifications and arresting proteins that regulate autophagy, organelles transport (neurotransmitters) and synapses.

Read more


Contact us